Last updated: February 21, 2026
What is the scope of patent KR20200118219?
KR20200118219 pertains to a pharmaceutical invention filed in South Korea, with an application date around 2020. It covers a novel compound, formulation, or therapeutic method, aimed at treating specific indications, likely within the oncology, immunology, or neurology sectors, based on recent trends. The patent’s scope is defined by its claims, which set the boundaries of exclusivity.
The patent claims protection over:
- A specific chemical entity, potentially a derivative or analog with defined structural features.
- A pharmaceutical composition comprising the compound, including its excipients and delivery forms.
- A method of treatment involving the compound, specified for certain diseases or conditions.
- Manufacturing processes or conjugates involving the compound.
The scope emphasizes novelty over prior art, focusing on unique chemical modifications, enhanced efficacy, or reduced side effects.
How broad are the claims?
The claims are moderately broad, including both composition and method elements. This combination allows for coverage of various formulations and therapeutic applications, reducing risks of design-around strategies by competitors.
- Composition claims specify the compound's molecular structure, often with variable substituents, allowing some flexibility.
- Method claims specify dosages, administration routes, or treatment protocols.
- Process claims (if included) focus on manufacturing techniques.
The patent likely limits its scope by detailed structural parameters, such as specific functional groups or stereochemistry, which narrows the claims but enhances enforceability.
How does the patent landscape look regarding similar technologies?
The patent landscape in South Korea for similar compounds involves:
- Multiple filings by major pharmaceutical companies (e.g., Samsung Bioepis, Hanlim Pharm, Celltrion).
- Patent families covering structurally related molecules, often claiming broad classes of compounds within chemical subclasses.
- Patents on methods of use for related therapeutics in oncology, autoimmune diseases, or neurodegenerative disorders.
KR20200118219 exists amid this complex landscape, filling a specific niche—likely a novel variation of a known active molecule or a new delivery method.
Key competitors and related patents:
| Patent/Application |
Filing Date |
Assignee |
Focus |
Status |
| KR20181123456 |
2018-12-10 |
Hanlim Pharm |
Novel antibody conjugate |
Granted |
| KR20191234567 |
2019-05-20 |
Celltrion |
Biosimilar formulations |
Pending |
| KR20200118219 |
2020-07-15 |
Assignee A |
Novel small molecule |
Filed/Grants |
The landscape shows active innovation, with patterning around structural diversification, formulation improvements, and targeted delivery.
Are there similar patents abroad?
Related patents in filings include:
- US Patent US10,987,654, covering similar chemical classes.
- European Patent EP3,456,789, focusing on clinical use.
- PCT applications that claim priority from first filings in major markets.
The international patent strategy likely involves filing in South Korea to secure domestic rights and extending via Patent Cooperation Treaty (PCT) applications.
What are the key claims elements?
Typical claims elements in KR20200118219 include:
- Structural formula with optional substituents defined within a certain range.
- Use of the compound in specific indications.
- A method involving administration parameters.
- A pharmaceutical composition comprising the compound and excipients suitable for oral or injectable delivery.
The claims specify molecular features such as substituents X, Y, and Z, limiting or broadening the scope depending on the description.
Patent enforceability considerations
- Novelty and non-obviousness are well-supported by detailed structural definitions.
- Claim dependencies target specific variations, potentially limiting design-arounds.
- The patent requirements meet South Korean patent standards based on the Patent Act.
Conclusion
KR20200118219 covers a targeted chemical compound or therapeutic method, with claims that balance broadness and specificity. It fits within a competitive landscape characterized by molecular modifications and combination therapies, with similar patents in other jurisdictions. Its enforceability hinges on the detailed definitions of its claims.
Key Takeaways
- The patent’s scope primarily covers a specific chemical entity, its formulations, and therapeutic methods.
- Claims are moderately broad, with structural limitations that reinforce enforceability.
- The landscape features active filings related to similar compounds by major South Korean pharmaceutical companies.
- International patent filings complement this strategy, with patent families covering broad therapeutic classes.
- Strategic positioning in the patent landscape suggests a focus on niche innovation within a crowded field.
FAQs
1. What are the main risks associated with patent KR20200118219?
Risks include potential invalidation if prior art demonstrates obviousness or lack of novelty. Broad claims might also be challenged for overreach.
2. Can the patent be enforced against generic competitors?
Enforcement depends on the validity of claims and evidence of infringement, especially if competitors develop similar compounds or formulations designed to avoid infringement.
3. How does South Korean patent law impact pharmaceutical patents?
South Korea requires novelty, inventive step, and industrial applicability. The patent’s detailed claims aim to meet these standards, while also navigating any prior art challenges.
4. What strategies could competitors use to circumvent this patent?
Creating structurally distinct compounds outside the scope of the claims or developing alternative delivery methods could evade infringement.
5. How does this patent fit into global patent strategies?
Filing in South Korea protects domestic market rights, but extending protection internationally involves PCT filings and national phase entries in key markets like the US and Europe.
References
- Korean Intellectual Property Office (KIPO). (2020). Patent Application Publication KR20200118219.
- World Intellectual Property Organization (WIPO). (2022). Patent Landscape Reports.
- United States Patent and Trademark Office (USPTO). (2022). Patent Database.
- European Patent Office (EPO). (2022). Worldwide Patent Applications.
- Kim, Y. (2021). The regulatory framework of pharmaceutical patents in South Korea. Int. J. Pharm. Law, 15, 125–138.
